These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 19540690)

  • 1. Tumor perfusion assessed by dynamic contrast-enhanced MRI correlates to the grading of renal cell carcinoma: initial results.
    Palmowski M; Schifferdecker I; Zwick S; Macher-Goeppinger S; Laue H; Haferkamp A; Kauczor HU; Kiessling F; Hallscheidt P
    Eur J Radiol; 2010 Jun; 74(3):e176-80. PubMed ID: 19540690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.
    Rosen MA; Schnall MD
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):770s-776s. PubMed ID: 17255308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined diffusion-weighted, blood oxygen level-dependent, and dynamic contrast-enhanced MRI for characterization and differentiation of renal cell carcinoma.
    Notohamiprodjo M; Staehler M; Steiner N; Schwab F; Sourbron SP; Michaely HJ; Helck AD; Reiser MF; Nikolaou K
    Acad Radiol; 2013 Jun; 20(6):685-93. PubMed ID: 23664397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging as a biomarker in renal cell carcinoma.
    Pedrosa I; Alsop DC; Rofsky NM
    Cancer; 2009 May; 115(10 Suppl):2334-45. PubMed ID: 19402070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphologic and dynamic renal imaging with assessment of glomerular filtration rate in a pcy-mouse model using a clinical 3.0 Tesla scanner.
    Sadick M; Schock D; Kraenzlin B; Gretz N; Schoenberg SO; Michaely HJ
    Invest Radiol; 2009 Aug; 44(8):469-75. PubMed ID: 19465861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring perfusion and permeability in renal cell carcinoma with dynamic contrast-enhanced MRI: a pilot study.
    Notohamiprodjo M; Sourbron S; Staehler M; Michaely HJ; Attenberger UI; Schmidt GP; Boehm H; Horng A; Glaser C; Stief C; Reiser MF; Herrmann KA
    J Magn Reson Imaging; 2010 Feb; 31(2):490-501. PubMed ID: 20099364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reproducibility of the aortic input function (AIF) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the kidneys in a volunteer study.
    Mendichovszky IA; Cutajar M; Gordon I
    Eur J Radiol; 2009 Sep; 71(3):576-81. PubMed ID: 19004588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of quantitative dynamic susceptibility-contrast MRI perfusion estimates obtained using different contrast-agent administration schemes at 3T.
    Wirestam R; Thilmann O; Knutsson L; Björkman-Burtscher IM; Larsson EM; Ståhlberg F
    Eur J Radiol; 2010 Jul; 75(1):e86-91. PubMed ID: 19720489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence.
    Franiel T; Lüdemann L; Rudolph B; Rehbein H; Staack A; Taupitz M; Prochnow D; Beyersdorff D
    Invest Radiol; 2008 Jul; 43(7):481-7. PubMed ID: 18580330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging.
    Uhl M; Saueressig U; van Buiren M; Kontny U; Niemeyer C; Köhler G; Ilyasov K; Langer M
    Invest Radiol; 2006 Aug; 41(8):618-23. PubMed ID: 16829744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1).
    De Bazelaire C; Rofsky NM; Duhamel G; Michaelson MD; George D; Alsop DC
    Acad Radiol; 2005 Mar; 12(3):347-57. PubMed ID: 15766695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Imaging tumor extension of renal cell carcinomas with magnetic resonance tomography. Improved tumor-tissue contrast with Gd-DTPA-assisted spin-echo sequences and simultaneous fat suppression].
    Venz S; Hierholzer J; Keske U; Friedrichs R; Schröder R; Siewert C; Hosten N; Felix R
    Aktuelle Radiol; 1998 May; 8(3):119-24. PubMed ID: 9645248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perfusion parameters analysis of the vertebral bone marrow in patients with Ph¹⁻ chronic myeloproliferative neoplasms (Ph(neg) MPN): a dynamic contrast-enhanced MRI (DCE-MRI) study.
    Courcoutsakis N; Spanoudaki A; Maris TG; Astrinakis E; Spanoudakis E; Tsatalas C; Prassopoulos P
    J Magn Reson Imaging; 2012 Mar; 35(3):696-702. PubMed ID: 22069235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
    Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
    Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma.
    Ficarra V; Martignoni G; Maffei N; Brunelli M; Novara G; Zanolla L; Pea M; Artibani W
    Cancer; 2005 Jan; 103(1):68-75. PubMed ID: 15573369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma.
    Dall'Oglio MF; Ribeiro-Filho LA; Antunes AA; Crippa A; Nesrallah L; Gonçalves PD; Leite KR; Srougi M
    J Urol; 2007 Aug; 178(2):425-8; discussion 428. PubMed ID: 17561167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of tumor blood flow in breast tumors with T1-dynamic contrast-enhanced MR imaging: impact of dose reduction and the use of a prebolus technique on diagnostic efficacy.
    Makkat S; Luypaert R; Sourbron S; Stadnik T; De Mey J
    J Magn Reson Imaging; 2010 Mar; 31(3):556-61. PubMed ID: 20187197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study.
    Cyran CC; Paprottka PM; Schwarz B; Sourbron S; Ingrisch M; von Einem J; Pietsch H; Dietrich O; Hinkel R; Bruns CJ; Reiser MF; Wintersperger BJ; Nikolaou K
    AJR Am J Roentgenol; 2012 Feb; 198(2):384-91. PubMed ID: 22268182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of chronic renal allograft nephropathy using contrast-enhanced MRI: a pilot study.
    Pereira RS; Gonul II; McLaughlin K; Yilmaz S; Mahallati H
    AJR Am J Roentgenol; 2010 May; 194(5):W407-13. PubMed ID: 20410386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of AIF ROI selection in DCE-MRI renography: reproducibility and variability of renal perfusion and filtration.
    Cutajar M; Mendichovszky IA; Tofts PS; Gordon I
    Eur J Radiol; 2010 Jun; 74(3):e154-60. PubMed ID: 19541441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.